Wolverine

BPC-157 upregulates VEGFR2 and nitric oxide signalling, drives angiogenesis into damaged tissue, and shows broad cytoprotection across rodent tendon, ligament, muscle, nerve and gut injury models. TB-500 works on a different axis entirely, sequestering G-actin to mobilise cells and promote their migration into the wound bed while reducing fibrotic scarring. The rationale for combining them is that one builds the supply line and the other moves the workforce, and because the mechanisms do not overlap there is no pharmacological conflict. What there is instead is a dosing conflict. BPC-157 is normally run at 250 to 500 mcg once or twice daily; TB-500 is normally run at 2 to 2.5 mg twice weekly during loading and once weekly thereafter. A one-to-one fixed blend cannot serve both schedules, so whichever component you dose correctly, you are dosing the other one wrong.

Targets: VEGFR2 and nitric oxide signalling, G-actin sequestration, Endothelial and fibroblast migration, Tendon and ligament fibroblast proliferation, Gastrointestinal mucosal integrity

• · This is how most people actually run it. 500 to 1,000 mcg of total blend gives 250 to 500 mcg of BPC-157 and 250 to 500 mcg of TB-500 per day, which is a textbook BPC-157 dose and works out to 1.75 to 3.5 mg of TB-500 per week - roughly standalone TB-500 maintenance, well under its 4 to 5 mg per week loading target. From a 20 mg vial in 2 mL you are drawing 5 to 10 units.
• · This hits the classic TB-500 loading dose of 2 to 2.5 mg twice weekly, but it also delivers 2 to 2.5 mg of BPC-157 in a single injection - four to ten times the usual dose - and only twice a week, which throws away the daily-exposure rationale that BPC-157's entire protocol rests on. It is the clearest possible demonstration of what a fixed ratio costs you. If you want a real TB-500 loading phase, buy TB-500 on its own.
• · The local placement is for the BPC-157 arm; TB-500 works systemically and gains nothing from being put near the injury. Never inject into a joint space or into the body of a tendon - that is a sterility and structural risk, not a targeting advantage.

Work out your exact syringe units →

• commonInjection-site redness, stinging or a small lump— Resolves within a day. Rotate sites.
• uncommonHead rush or lightheadedness shortly after injection— Usually attributed to the TB-500 component and passes in minutes.
• uncommonFatigue or a flat, washed-out feeling in the first week— Reported more with the loading-weighted protocol than with daily dosing.
• uncommonLoose stools or mild gut upset— Usually the BPC-157 arm and typically settles within a week.
• rareUnwanted tissue growth from sustained pro-angiogenic signalling— Theoretical rather than documented, but it is the mechanistic reason not to run this indefinitely and the reason active malignancy is a contraindication.

• Active or recent malignancy - both components are pro-angiogenic.
• Pregnancy and breastfeeding - no data of any kind.
• Drug-tested athletes - BPC-157 and TB-500 are both WADA-prohibited.
• Any undiagnosed lump, mass or unexplained bleeding until it has been investigated.

• redundantbpc-157 — Half of this vial is BPC-157. Adding a standalone BPC-157 protocol on top is straightforward double-dosing.
• redundanttb-500 — The other half. Running a separate 2 mg twice-weekly TB-500 course alongside daily Wolverine takes weekly TB-500 far beyond any protocol anyone has described.
• redundantthymosin-beta-4 — TB-500 is a fragment of thymosin beta-4 and shares its target. Running both pays twice for one mechanism.
• redundantglow — GLOW already contains both BPC-157 and TB-500. Stacking Wolverine on top of GLOW doubles both while adding a large copper load you may not have intended.
• redundantklow — Same overlap as GLOW, plus KPV.
• synergyipamorelin-cjc-1295-blend — An extremely common recovery stack. The mechanisms are unrelated so there is no pharmacological conflict, but there is also no trial data on the combination.
• cautionNSAIDs — Rodent work suggests BPC-157 protects the gut against NSAID damage, which is a real part of its appeal, but it should not be read as licence to keep taking NSAIDs through an injury that needs to remodel.

• · Track the specific injury with a fixed measure - range of motion, pain on a defined loaded movement - rather than general impression, because both components are slow and easy to over-credit.
• · Confirm from the label whether the milligram figures are per component or total before your first dose.
• · Stop and get any new lump or mass looked at rather than assuming it is unrelated.
• · Note that neither peptide fixes a mechanical problem; if a tendon needs load management or a joint needs imaging, this blend will not substitute for it.

Neither component is an approved drug and both are sold as research chemicals. In April 2026 the FDA removed BPC-157 and TB-500 from the Category 2 bulk drug substances list, and on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend both for the 503A Bulks List; the vote is non-binding and the FDA has not acted on it. A pre-mixed two-peptide blend is a further step removed from anything compoundable. Both peptides are prohibited by WADA at all times.

• Sikiric et al., stable gastric pentadecapeptide BPC 157 in tendon, ligament and muscle healing - preclinical review (review)
• Goldstein, Hannappel & Kleinman, thymosin beta-4 in tissue repair and regeneration (review)
• RGN-259 thymosin beta-4 ophthalmic clinical trial programme in dry eye and neurotrophic keratopathy (trial)
• Vendor labels and certificates of analysis for BPC-157 / TB-500 blend vials in 5+5, 10+10 and 30+30 mg presentations (other)

Wolverine is the blend where the pharmacology is fine and the pharmacokinetics are the problem, so this section is mostly about timing. BPC-157's mechanism, stripped of enthusiasm, is vascular. The reproducible findings across the Sikiric literature are increased VEGFR2 expression and activation of the VEGFR2-Akt-eNOS axis, rapid formation of collateral vessels bypassing an occlusion, and bidirectional modulation of nitric oxide - it opposes L-NAME-induced hypertension and also opposes L-arginine-induced hypotension. It counteracts the effects of a startlingly wide range of insults in rodents, from NSAID gut lesions to severed tendon to spinal cord injury. That breadth is the strongest and weakest thing about it. A compound that restores perfusion and endothelial function will look effective in almost any injury model, and it will also look effective in models where the true mechanism is something else entirely. There is still no identified receptor after twenty-five years, which means every mechanism above is inference from downstream observation. TB-500 works on cell mobility rather than blood supply. Thymosin beta-4 is the dominant intracellular G-actin sequestering protein, and the proposed extracellular action is to shift the actin monomer pool in a way that favours migration - endothelial cells, keratinocytes and progenitor cells moving into a wound bed - alongside reported anti-fibrotic effects that reduce scar formation during remodelling. The complementarity claim is real: one component recruits blood supply, the other recruits cells, and they do not compete for a target. The conflict is temporal, and it is worth being precise about it. BPC-157 clears in under thirty minutes and its standalone protocol is built on daily or twice-daily exposure. TB-500's effect persists for days and its standalone protocol is 2 to 2.5 mg twice weekly loading, then weekly. Those are not compatible schedules. Run the blend daily at a correct BPC-157 dose and you are giving 1.75 to 3.5 mg of TB-500 per week - fine, roughly maintenance, but you will never reach a real loading phase. Run it twice weekly at a correct TB-500 loading dose and you are giving 2 to 2.5 mg of BPC-157 in one hit, four to ten times the usual dose, on two days out of seven. Given that BPC-157 clears in half an hour, five days a week with no BPC-157 in the system is not a version of the protocol anyone has ever advocated. The daily-weighted schedule is the right compromise and it is what most people run. Understand that you are choosing to dose BPC-157 correctly and TB-500 approximately, and that this is a decision the vial made for you.

The first failure is the loading protocol. Someone reads that TB-500 loads at 2 to 2.5 mg twice weekly, applies that to the blend, and injects 4 to 5 mg of total product twice a week. That delivers 2 to 2.5 mg of BPC-157 in a single shot - four to ten times the standard dose - and then leaves five days with nothing, when the measured half-life is under thirty minutes. Every rationale for BPC-157 dosing is thrown away. If you want to load TB-500, buy TB-500. The second is the label. Vendors sell this as 5+5, 10+10 and 30+30 mg presentations and describe them inconsistently - a 20 mg vial can mean 10 mg of each or 20 mg of each. Getting it wrong halves or doubles everything. Confirm from the certificate of analysis, then compute mg/mL yourself. The third is the TB-500 identity problem. If the vendor shipped full-length thymosin beta-4 rather than the short fragment, the same milligram figure is roughly six times fewer molecules. Nobody can tell the difference by looking, and most certificates of analysis will not clarify it. The fourth is injecting into the wrong place. Near-site subcutaneous injection is fine and is the sensible way to run the BPC-157 arm for a localised injury. Injecting into a joint space or into the body of a tendon is a sterility risk and a structural risk with no targeting benefit, and people do it because they think closer means better. The fifth is masking. Both components appear to reduce pain in an injured structure. Pain is load-limiting for a reason. Feeling better and then returning to full load on a tendon that has not remodelled is a good way to convert a manageable tendinopathy into a rupture. Progress your loading on time, not on symptoms. The sixth is running it forever. There is no defined stopping point built into the product, both components are pro-angiogenic, and there is zero long-term human safety data. The practical stopping rule is simpler than any calendar: when the injury stops improving week on week, stop. People who take it continuously for years are running an uncontrolled experiment on angiogenic signalling with no reason to expect a benefit past the healing phase. The seventh, for anyone tested, is that both peptides are WADA-prohibited at all times. This is not a grey area and detection methods exist.

1. 500 mcgWeek 1 — 500 mcg of total blend daily - 250 mcg each of BPC-157 and TB-500. From a 20 mg vial in 2 mL this is 5 units. There is not much to titrate here, since both compounds have famously flat dose-response curves in the rodent literature, so this step is about confirming you do not react at the injection site and that your gut settles.
2. 1 mgWeeks 2 to 6 — 1,000 mcg of total blend daily - 500 mcg each. This is a textbook standalone BPC-157 dose and delivers 3.5 mg of TB-500 per week, which is between standalone maintenance and loading. It is the best compromise the fixed ratio allows and it is where the protocol should live.
3. 1 mgWeeks 6 to 8 — Hold and assess against your fixed injury measure, not against how you feel. If the injury has stopped improving week on week, the blend has done what it is going to do and continuing is spending money on a pro-angiogenic compound for no return.
4. —After week 8 — Stop. Take a break at least as long as the run. There is no maintenance dose for this blend with any evidence behind it, and the reason to stop is not tolerance or receptor exhaustion but the total absence of long-term human safety data for two pro-angiogenic compounds.

• VEGFR2 (KDR) and the Akt-eNOS axis

  Increased VEGFR2 expression and internalisation with downstream Akt phosphorylation and eNOS-derived nitric oxide. This is the best-supported BPC-157 mechanism and the basis for the angiogenesis and collateral-vessel findings. No direct binding has been shown.

• Nitric oxide synthase system

  Bidirectional modulation - BPC-157 counteracts both NO blockade and NO excess in rodent models. The most reproducible signature it has, and a good explanation for why it appears to help such a wide range of injuries.

• FAK-paxillin pathway in tendon fibroblasts

  Reported increase in tendon fibroblast migration, survival and F-actin formation, which is the cell-level basis for the tendon claims this blend is bought for.

• Growth hormone receptor expression in tendon fibroblasts

  BPC-157 has been reported to upregulate GH receptor expression in tendon fibroblasts, offered as a mechanism for enhanced local proliferation. Preclinical and from a single research lineage.

• G-actin (monomeric actin)

  The TB-500 arm. Sequesters actin monomers, shifting the polymerisation equilibrium to favour cell migration into damaged tissue and reducing fibrotic scarring during remodelling. Micromolar-range binding is reported for full-length thymosin beta-4; no verified figure for the fragment.

• No identified receptor for either component

  Stated plainly because it defines the evidence quality of this entire product. Neither BPC-157 nor the TB-500 fragment has a characterised binding site. Everything above is downstream observation in rodents.

• Thymosin beta-4 (RGN-259) ophthalmic solution in severe dry eye - randomised phase 2 Phase 2 · 2015

  Improvement in signs and symptoms of severe dry eye versus vehicle. Reported as significantly improving both. Listed here because it is the only genuine human efficacy data anywhere near either component of this blend - and it used full-length thymosin beta-4, applied to the eye, not the TB-500 fragment injected subcutaneously.

• Thymosin beta-4 ophthalmic solution for dry eye, controlled adverse environment model - randomised placebo-controlled phase 2 Phase 2 · 2015

  Ocular discomfort and corneal staining in a controlled adverse environment challenge. Same caveat as above: full-length protein, topical ocular route, nothing to do with injected TB-500 for tendon repair.

Days 1 to 7: nothing reliable. Some people report an injection-site sting and a mild head rush attributed to the TB-500 arm, and transient loose stools from the BPC-157 arm that settle within a week. Anyone reporting injury improvement in the first few days is describing something other than tissue repair. Weeks 2 to 4: this is the honest window for a first signal. Reduced ache in a chronic tendinopathy, better tolerance of a loaded movement, faster settling after training. Gut effects from the BPC-157 arm often show earlier than musculoskeletal ones, sometimes within the first ten days. Weeks 4 to 8: where the meaningful change happens if it is going to. Tendon and ligament remodelling is slow biology and no peptide compresses it into days. Track it with a fixed measure taken the same way each time, because the difference between real improvement and the natural history of an injury that was going to settle anyway is not something you can feel. Week 8 onward: assess and stop. If your fixed measure has plateaued for two to three weeks, the blend has finished contributing. After stopping: the TB-500 arm has a tail of days because its tissue effect outlasts its plasma presence. The BPC-157 arm is gone within hours as a molecule. Whatever structural repair happened persists - it is tissue, not a drug effect - which is why the correct model for this blend is a course during a healing phase, not an ongoing supplement.

This is the blend people build stacks around, so the notes are about what genuinely adds and what merely costs. The GH secretagogue pairing - ipamorelin with CJC-1295, or the tesamorelin triple - is the most common addition and the most defensible. The mechanisms are unrelated, there is no pharmacological conflict, and raising IGF-1 during a repair phase has a coherent rationale. There is no trial of the combination and no reason to expect harm. If you are going to add one thing, this is the one with the least objectionable logic. Adding standalone TB-500 to reach a proper loading phase is the stack that most tempts people and it needs care. Two milligrams twice weekly on top of daily Wolverine takes weekly TB-500 to 5.5 mg or more, beyond anything described in any protocol. If you want a loading phase, the correct move is to buy TB-500 separately and run Wolverine at a lower daily dose, or simply buy both components separately from the start. Collagen peptides at 10 to 15 g with vitamin C, taken 30 to 60 minutes before loading the injured tendon, is the adjunct with the best human evidence in this entire section - and it has better evidence than either peptide in the vial. It is cheap and it is not a peptide-vendor product, which is presumably why it gets mentioned less. NSAIDs are the interaction worth thinking about properly. BPC-157's protection against NSAID-induced gut lesions is one of its most reproducible rodent findings, and it is genuinely part of why people take it. That is not a licence to keep taking NSAIDs through a tendon injury, because chronic NSAID use during tendon remodelling has its own problems that BPC-157 does nothing about. Creatine, protein and progressive loading are not stack items, they are the actual treatment. Neither peptide fixes a mechanical problem. A tendon that needs graded loading needs graded loading, and the most common way this blend disappoints is that it was asked to substitute for rehab. Do not stack with GLOW or KLOW - both already contain BPC-157 and TB-500, and GLOW adds a copper load you did not ask for.

Against buying BPC-157 and TB-500 separately: separate vials are the better protocol and it is not a close call. You get daily BPC-157 at 250 to 500 mcg and TB-500 at 2 to 2.5 mg twice weekly during loading then weekly after - which is how both compounds are actually dosed by anyone who reads about them individually. The blend cannot produce that pattern at any unit count. Buying separately costs a little more and means two vials instead of one. That is the entire trade-off, and for a serious injury it is worth making. Against standalone BPC-157: for a gut problem, standalone BPC-157 is clearly better - it can be taken orally, it is stable in gastric juice, and TB-500 contributes nothing to a mucosal problem. For a tendon, the case for adding TB-500 is mechanistic rather than evidenced, so standalone BPC-157 is a defensible cheaper choice. Against GLOW: GLOW contains both of these plus a large copper load and caps your cycle at four to eight weeks because of it. For an injury, Wolverine is better in every respect. Against PRP, prolotherapy or a shockwave course: all three have more human data than this blend, and physiotherapy with progressive loading has vastly more. Wolverine is cheaper than any of them and requires nothing but a syringe, which is its real advantage and also the reason it gets used instead of treatment rather than alongside it. Against doing the rehab properly: no peptide changes the mechanics of a tendon that is being loaded wrong. The best outcomes reported with this blend are in people who ran it alongside a structured loading programme, and there is no way to know how much of that was the programme.

$45–$130/month. A 20 mg vial run at 1,000 mcg daily lasts about twenty days, so a month is roughly one and a half vials. Grey-market pricing for 10+10 mg vials has generally been in the thirty to eighty dollar range, with larger 30+30 presentations offering better value per milligram. Add water and syringes. This is the cheapest of the flagship blends to run and one reason it is the most popular. Observed market ranges, not verified against current vendor pricing in this session.

• ?The one-to-one ratio has no published rationale and actively conflicts with how each component is dosed alone. I found nothing suggesting it was chosen for any reason other than convenience.
• ?No study of any kind has tested BPC-157 and TB-500 together, in any species, at any dose. The synergy claim is entirely mechanistic reasoning.
• ?TB-500 has no published pharmacokinetics. The days-long duration of effect that justifies weekly dosing is inferred from tissue-effect persistence in animal models, not from measurement, and I could not resolve a primary source for it in this session.
• ?The BPC-157 pharmacokinetic figures are from rats and beagle dogs. Bioavailability differed roughly three-fold between the two species, so extrapolating to humans is guesswork in either direction. No human PK study exists.
• ?The measured intramuscular bioavailability does not necessarily apply to the subcutaneous route almost everyone actually uses.
• ?No verified binding affinity figure was resolved for TB-500 or thymosin beta-4 to G-actin, so that field is left empty.
• ?Which molecule is actually in a TB-500 vial - the short acetylated fragment or full-length thymosin beta-4 - varies by vendor and is rarely stated clearly. This changes the molar dose per milligram substantially.
• ?Molecular weights for both components are omitted deliberately; neither was verified in this session.
• ?The pro-angiogenic cancer concern is mechanistic reasoning, not a documented outcome. No case series links either peptide to tumour progression in humans, and equally no study has looked.
• ?Whether BPC-157's flat dose-response in rodents means dose genuinely does not matter, or means the models were saturated, is unresolved and matters a great deal for how you dose.
• ?The two thymosin beta-4 ophthalmic trials are verified as existing and as phase 2, but I did not resolve their participant numbers or durations, so those fields are null.
• ?Cost ranges come from general market observation and were not verified against current vendor pricing this session.
• ?Component sequences in the modifications array are established chemistry but were not independently resolved this session, hence verified false.

• Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M, Frontiers in Pharmacology, 2022 · PMID 36588717

  The most useful single paper for anyone running this blend. Half-life under 30 minutes, linear kinetics, intramuscular bioavailability 14 to 19 percent in rats and 45 to 51 percent in dogs, urine and bile elimination, complete hydrolysis to amino acids. The half-life figure is what makes the twice-weekly loading protocol indefensible.

• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Sikiric P, et al, Frontiers in Pharmacology, 2021 · PMID 34267654

  The core wound-healing mechanism review including the VEGFR2 and nitric oxide work that everything in this record's mechanism section rests on.

• BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Sikiric P, et al, Current Pharmaceutical Design, 2018 · PMID 29998800

  The tendon, ligament, muscle and bone healing literature specifically, which is what this blend is sold for. Note it is a review by the group that generated the underlying data.

• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM, Current Reviews in Musculoskeletal Medicine, 2025 · PMID 40789979

  Independent 2025 review of BPC-157 for musculoskeletal use, written for clinicians rather than by the originating group. If you read one paper before running this blend for an injury, make it this one.

• Injectable Therapeutic Peptides - An Adjunct to Regenerative Medicine and Sports Performance? DeFoor MT, Dekker TJ, Arthroscopy, 2025 · PMID 39265666

  Sports medicine perspective on injectable peptides including this pairing, useful for calibrating how the orthopaedic literature actually regards these compounds as opposed to how they are marketed.

• Advances in the basic and clinical applications of thymosin beta4 Goldstein AL, Kleinman HK, Expert Opinion on Biological Therapy, 2015 · PMID 26096726

  The thymosin beta-4 reference review. Read the distinction between the full-length protein studied here and the fragment in your vial, because that distinction is the entire basis of the TB-500 evidence claim.

• Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide Philp D, Kleinman HK, Annals of the New York Academy of Sciences, 2010 · PMID 20536453

  The animal wound-healing and anti-fibrotic evidence for the TB-500 arm, including the reduced-scarring claim.

• Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial Sosne G, Dunn SP, Kim C, Cornea, 2015 · PMID 25826322

  One of the only randomised human trials of thymosin beta-4 in any form. Ophthalmic, full-length protein, topical. It is the source of the claim that TB-500 has clinical data, and reading it shows how far that claim has been stretched.

• Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model Sosne G, Ousler GW, Clinical Ophthalmology, 2015 · PMID 26056426

  The companion phase 2 ophthalmic trial. Same point - real human data, wrong molecule and wrong route for what you are doing with it.